New hope for lymphoma patients: glofitamab combo faces standard care in trial
NCT ID NCT07599423
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the immunotherapy drug glofitamab to standard chemotherapy (gemcitabine and oxaliplatin) works better than usual treatments for people with large B-cell lymphoma that has returned or not responded to first therapy. About 96 adults will be randomly assigned to get either the new combo or standard care, which may include a stem cell transplant. The main goal is to see how long patients stay free of cancer progression or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glofitamab (a drug that helps the immune system attack cancer cells) combined with gemcitabine and oxaliplatin (chemotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with hard-to-treat large B-cell lymphoma that has come back or not responded to initial therapy.
What could go wrong
This is a Phase 2 trial with only 96 participants, so results are preliminary. The drug combination may cause serious side effects like cytokine release syndrome, and it may not work better than current standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••